Chao He

Chao He

Auto-generated profile, based on publicly available information

Chao He

School of pharmaceutical sciences (Shenzhen), Sun Yat-sen University, Shenzhen, China

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 October 2023 in Journal of Extracellular Vesicles
Verified
Journal Article
Open access
RHRufan Huang
Rufan Huang
BJBo Jia
Bo Jia
DSDandan Su
Dandan Su
MLManchun Li
Manchun Li
ZXZhanxue Xu
Zhanxue Xu
FCFang Cheng
Fang Cheng
Existing therapeutics for autoimmune diseases remain problematic due to low efficacy, severe side effects, and difficulties to reach target tissues. Herein, we design multifunctional fusion nanovesicles that can target lesions for the treatment of autoimmune skin diseases. The grapefruit‐derived exosome‐like nanovesicles (GEVs) with anti‐inflammatory and antioxidant effects are first encapsulated with CX5461, an immunosuppressant with anti‐proliferative properties to form GEV@CX5461. In order to enhance therapeutic efficiency and safety, GEV@CX5461 are then fused with CCR6+ nanovesicles derived from membranes of engineered gingiva‐derived mesenchymal stem cells (GMSCs). The resulting FV@CX5461 not only maintain the bioactivity of GEVs, CX5461, and GMSC membranes but also home to inflamed tissues rich in chemokine CCL20 through the chemotaxis function of CCR6 on FVs. Moreover, FV@CX5461 reduce the secretion of inflammatory factors, calm down Th17 cell activation, and induce Treg cell infiltration. Finally, impressive therapeutic efficiency in both psoriasis and atopic dermatitis disease models is demonstrated using FV@CX5461 to reshape the unbalanced immune microenvironment. A nanotherapeutic drug delivery strategy is developed using fusion nanovesicles derived from plant and animal cells with high clinical potential.

10 December 2020 in Biomaterials Science
Verified
Journal Article
Closed access
PDF file
MYMin Yang
Min Yang
ZXZhanxue Xu
Zhanxue Xu
HYHailan Yan
Hailan Yan
HTHsiang-i Tsai
Hsiang-i Tsai
DSDandan Su
Dandan Su
FCFang Cheng
Fang Cheng
Organ transplantation has been employed upon serious injuries, but a T-cell-mediated potent inflammatory immune response often leads to graft rejection. Immunosuppressive drugs such as rapamycin (RAPA) have to be taken after organ transplantation, but long-term use of these drugs causes severe adverse effects. Immune checkpoint pathways such as the programmed death-receptor 1/programmed death-ligand 1 (PD-1/PD-L1) provides an immunosuppressive environment, preventing excessive tissue destruction due to inflammatory immune responses. In this study, we bioengineered cell membrane-derived PD-L1 nanovesicles (PD-L1 NVs) to carry low doses of RAPA. These NVs inhibited T-cell activation and proliferation in vitro, by enhancing the PD-1/PD-L1 immune co-inhibitory signaling axis and inhibiting the mTOR pathway. Importantly, PD-L1 NVs encapsulated with rapamycin exerted stronger effects on inhibiting T-cell proliferation than PD-L1 NVs or rapamycin alone. This can be recapitulated in a mouse skin transplantation model, leading to the weakened alloimmune response and allograft tolerance. We also found that PD-L1/rapamycin vesicles have additional function to induce regulatory T cells in the recipient spleens. Our study highlighted the power of combining low-dose rapamycin and PD-L1 in the nanovesicles as immunosuppressants to promote allograft acceptance.

27 December 2024 in Biomaterials
Verified
Journal Article
Closed access
YXYue Xiong
Yue Xiong
CHChao He
Chao He
JQJunyang Qi
Junyang Qi
MXMeimei Xiong
Meimei Xiong
SLShuna Liu
Shuna Liu
WDWenbin Deng
Wenbin Deng

1 September 2018 in Neuroscience Bulletin
Verified
Journal Article
Closed access
PDF file
JGJian Guan
Jian Guan
MZMiao Zhao
Miao Zhao
CHChao He
Chao He
XLXue Li
Xue Li
YLYing Li
Ying Li
GQGuo-Fen Qiao
Guo-Fen Qiao

7 July 2025 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
CHChao He
Chao He
YXYue Xiong
Yue Xiong
YZYuqing Zeng
Yuqing Zeng
JFJianhua Feng
Jianhua Feng
FYFuxia Yan
Fuxia Yan
FCFang Cheng
Fang Cheng
Recent studies have shown that the interaction between acute myeloid leukemia (AML) and bone marrow stromal cells (BMSCs) plays a vital role in the progression of leukemia and the development of drug resistance, while the underlying mechanisms remain inconclusive. In this study, we found that AML patient-derived BMSCs exhibit a hyperinflammatory phenotype. Histone deacetylase 3 (HDAC3) in BMSCs enhances mitochondrial reactive oxygen species (ROS) production by RAB5A-mediated blockade of mitophagy. Furthermore, we confirmed that HDAC3 regulates RAB5A expression through transcription factor YY1. Excessive ROS accelerates the senescence of BMSCs and promotes the secretion of senescence-associated secretory phenotype, creating a hyperinflammatory bone marrow niche, activating the NF-κB pathway in AML cells to promote their survival and drug resistance. The inhibition of HDAC3 in BMSCs reduces the mitochondrial ROS production and thus delays BMSCs senescence. Consequently, HDAC3 inhibition in BMSCs decreases AML proliferation and synergizes with the anti-AML efficacy of venetoclax. Therefore, our study suggests that targeting HDAC3 in BMSCs may be used for the combination therapy of AML by remodeling the AML-supportive niche.

1 June 2025 in Biophysics Reviews
Verified
Journal Article
Closed access
YWYu Wang
Yu Wang
HJHao Jiang
Hao Jiang
ZSZhenwei Su
Zhenwei Su
RWRan Wang
Ran Wang
XLXinyuan Luo
Xinyuan Luo
CHChao He
Chao He
Acute myeloid leukemia (AML) is a hematologic cancer. Cytarabine-based chemotherapy is the primary treatment. However, drug resistance presents a significant challenge leading to treatment failure. Our study explores the underlying correlation between AML stiffness and its drug resistance feature. We employed microfluidic technology to measure AML cell deformability, demonstrating that drug-resistant cells exhibit increased stiffness compared to their drug-sensitive counterparts. Transcriptomic analysis revealed that enhanced stiffness in drug-resistant cells is associated with upregulated cytoskeletal protein expression and increased lipid metabolism, particularly the peroxisome proliferators-activated receptor (PPAR) signaling pathway. Mechanistically, we found that knocking down PLIN2 at the genetic level and increasing the cholesterol level promoted the deformation of drug-resistant cells, indicating that intracellular lipid levels are involved in the regulation of cell softness. Our findings suggest that AML cell stiffness could serve as a potential biomarker for drug resistance, providing new insights into the mechanisms underlying AML drug resistance and offering potential therapeutic targets.